P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in KoreaECCO '18 Vienna
2018
P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBDECCO '18 Vienna
2018
P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinibECCO '18 Vienna
2018
P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort studyECCO '18 Vienna
2018
P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysisECCO '18 Vienna
2018
P515: Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trialECCO '18 Vienna
2018
P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trialsECCO '18 Vienna
2018
P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months resultsECCO '18 Vienna
2018
P520: Gastrointestinal ultrasonography in pregnant patients with IBD is useful in the identification of active intestinal inflammationECCO '18 Vienna
2018
P521: Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practiceECCO '18 Vienna
2018
P522: Soluble sMadCAM1 and retinoic acid are potential tools for therapeutic drug monitoring in inflammatory bowel disease s under vedolizumab: A proof of conceptECCO '18 Vienna
2018
P523: New guidance on therapeutic drug monitoring; potential clinical and cost implicationECCO '18 Vienna
2018
P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluationECCO '18 Vienna
2018
P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centreECCO '18 Vienna
2018